221 related articles for article (PubMed ID: 8727138)
1. Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study.
Salazar AM; Levy HB; Ondra S; Kende M; Scherokman B; Brown D; Mena H; Martin N; Schwab K; Donovan D; Dougherty D; Pulliam M; Ippolito M; Graves M; Brown H; Ommaya A
Neurosurgery; 1996 Jun; 38(6):1096-103; discussion 1103-4. PubMed ID: 8727138
[TBL] [Abstract][Full Text] [Related]
2. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Rosenfeld MR; Chamberlain MC; Grossman SA; Peereboom DM; Lesser GJ; Batchelor TT; Desideri S; Salazar AM; Ye X
Neuro Oncol; 2010 Oct; 12(10):1071-7. PubMed ID: 20615924
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.
Migliorini D; Dutoit V; Allard M; Grandjean Hallez N; Marinari E; Widmer V; Philippin G; Corlazzoli F; Gustave R; Kreutzfeldt M; Blazek N; Wasem J; Hottinger A; Koka A; Momjian S; Lobrinus A; Merkler D; Vargas MI; Walker PR; Patrikidou A; Dietrich PY
Neuro Oncol; 2019 Jul; 21(7):923-933. PubMed ID: 30753611
[TBL] [Abstract][Full Text] [Related]
4. Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group.
Giantonio BJ; Hochster H; Blum R; Wiernik PH; Hudes GR; Kirkwood J; Trump D; Oken MM
Invest New Drugs; 2001; 19(1):89-92. PubMed ID: 11291838
[TBL] [Abstract][Full Text] [Related]
5. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.
Butowski N; Lamborn KR; Lee BL; Prados MD; Cloughesy T; DeAngelis LM; Abrey L; Fink K; Lieberman F; Mehta M; Ian Robins H; Junck L; Salazar AM; Chang SM
J Neurooncol; 2009 Jan; 91(2):183-9. PubMed ID: 18850068
[TBL] [Abstract][Full Text] [Related]
6. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.
Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Normolle DP; Connelly AK; Dibridge S; Mason G; Whiteside TL; Okada H
Neuro Oncol; 2016 Aug; 18(8):1157-68. PubMed ID: 26984745
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.
Kyi C; Roudko V; Sabado R; Saenger Y; Loging W; Mandeli J; Thin TH; Lehrer D; Donovan M; Posner M; Misiukiewicz K; Greenbaum B; Salazar A; Friedlander P; Bhardwaj N
Clin Cancer Res; 2018 Oct; 24(20):4937-4948. PubMed ID: 29950349
[No Abstract] [Full Text] [Related]
8. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).
Butowski N; Chang SM; Junck L; DeAngelis LM; Abrey L; Fink K; Cloughesy T; Lamborn KR; Salazar AM; Prados MD
J Neurooncol; 2009 Jan; 91(2):175-82. PubMed ID: 18797818
[TBL] [Abstract][Full Text] [Related]
9. Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors.
Hartman LL; Crawford JR; Makale MT; Milburn M; Joshi S; Salazar AM; Hasenauer B; VandenBerg SR; MacDonald TJ; Durden DL
J Pediatr Hematol Oncol; 2014 Aug; 36(6):451-7. PubMed ID: 24309609
[TBL] [Abstract][Full Text] [Related]
10. [Effect of interferon inducer (poly ICLC) in the treatment of malignant brain tumor (author's transl)].
Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
No To Shinkei; 1982 Mar; 34(3):267-73. PubMed ID: 7093065
[TBL] [Abstract][Full Text] [Related]
11. Dose and regimen effects of poly ICLC, an interferon inducer, in a multi-dose bleomycin model of interstitial pulmonary fibrosis.
Wild JS; Hyde DM; Giri SN
Pharmacol Toxicol; 1994 Jul; 75(1):42-8. PubMed ID: 7526360
[TBL] [Abstract][Full Text] [Related]
12. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.
Okada H; Kalinski P; Ueda R; Hoji A; Kohanbash G; Donegan TE; Mintz AH; Engh JA; Bartlett DL; Brown CK; Zeh H; Holtzman MP; Reinhart TA; Whiteside TL; Butterfield LH; Hamilton RL; Potter DM; Pollack IF; Salazar AM; Lieberman FS
J Clin Oncol; 2011 Jan; 29(3):330-6. PubMed ID: 21149657
[TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced ovarian cancer with polyinosinic-polycytidylic lysine carboxymethylcellulose (poly(ICLC)).
Rettenmaier MA; Berman ML; DiSaia PJ
Gynecol Oncol; 1986 Jul; 24(3):359-61. PubMed ID: 3721308
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic guided laser-induced interstitial thermotherapy (SLITT) in gliomas with intraoperative morphologic monitoring in an open MR: clinical expierence.
Leonardi MA; Lumenta CB
Minim Invasive Neurosurg; 2002 Dec; 45(4):201-7. PubMed ID: 12494354
[TBL] [Abstract][Full Text] [Related]
15. Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects.
Ewel CH; Urba WJ; Kopp WC; Smith JW; Steis RG; Rossio JL; Longo DL; Jones MJ; Alvord WG; Pinsky CM
Cancer Res; 1992 Jun; 52(11):3005-10. PubMed ID: 1591717
[TBL] [Abstract][Full Text] [Related]
16. Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death.
Kende M; Lupton HW; Rill WL; Gibbs P; Levy HB; Canonico PG
Antimicrob Agents Chemother; 1987 Aug; 31(8):1194-8. PubMed ID: 3631943
[TBL] [Abstract][Full Text] [Related]
17. Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC.
Wong JP; Yang H; Nagata L; Kende M; Levy H; Schnell G; Blasetti K
Vaccine; 1999 Mar; 17(13-14):1788-95. PubMed ID: 10194841
[TBL] [Abstract][Full Text] [Related]
18. Enhanced induction of plasma interferon after subcutaneous administration in rabbits of poly ICLC with albumin.
Pessina GP; Muscettola M; Paulesu L; Bocci V
J Biol Regul Homeost Agents; 1989; 3(3):118-21. PubMed ID: 2483023
[TBL] [Abstract][Full Text] [Related]
19. Phase I-II trials of poly(ICLC) in malignant brain tumor patients.
Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
J Interferon Res; 1982; 2(1):1-4. PubMed ID: 6180095
[TBL] [Abstract][Full Text] [Related]
20. Preliminary trial of poly ICLC in chronic progressive multiple sclerosis.
Bever CT; Salazar AM; Neely E; Ferraraccio BE; Rose JW; McFarland HF; Levy HB; McFarlin DE
Neurology; 1986 Apr; 36(4):494-8. PubMed ID: 3960323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
